Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01245062




Registration number
NCT01245062
Ethics application status
Date submitted
18/11/2010
Date registered
22/11/2010
Date last updated
5/04/2018

Titles & IDs
Public title
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Scientific title
A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Secondary ID [1] 0 0
114267
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK1120212
Treatment: Drugs - Chemotherapy

Experimental: GSK1120212 - MEK inhibitor

Active Comparator: Chemotherapy - Investigator Choice of DTIC or paclitaxel

Experimental: Crossover - MEK inhibitor after documented progression on Chemotherapy Arm


Treatment: Drugs: GSK1120212
MEK inhibitor

Treatment: Drugs: Chemotherapy
Investigator Choice of DTIC or paclitaxel

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review - Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression (PD) or death. PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer participants improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Primary Efficacy Population included all participants with BRAF V600E mutation-positive melanoma without a history of brain metastases.
Timepoint [1] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [1] 0 0
Progression-free Survival in All Participants - PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed and BRIC-assessed PFS were summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Intend-To-Treat (ITT) Population included all randomized participants regardless of whether or not treatment was administered.
Timepoint [1] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [2] 0 0
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and Without Prior Chemotherapy as Assessed by the Investigator - PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Timepoint [2] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [3] 0 0
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and With Prior Chemotherapy as Assessed by the Investigator - PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Timepoint [3] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [4] 0 0
Overall Survival in All Participants - Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
Timepoint [4] 0 0
Day 1 until death due to any cause (average of 20.3 months)
Secondary outcome [5] 0 0
Overall Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases - Overall survival was defined as the time from the date of randomization to the date of death due to any cause. NA indicates data was not available.
Timepoint [5] 0 0
Day 1 until death due to any cause (average of 20.3 months)
Secondary outcome [6] 0 0
Number of BRAF V600E Mutation-positive Participants Without a History of Brain Metastases With Overall Response (OR) as Assessed by the Investigator and Independent Review - OR is defined as the number of participants with evidence of complete response (CR; disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
Timepoint [6] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [7] 0 0
Number of Participants With OR as Assessed by the Investigator and Independent Review - OR is defined as the number of participants with evidence of complete response (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
Timepoint [7] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [8] 0 0
Number of BRAF V600E Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator - OR is defined as the number of participants with evidence of complete response (disappearance of all extranodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
Timepoint [8] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [9] 0 0
Number of BRAF V600K Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator - OR is defined as the number of participants with evidence of complete response (CR; disappearance of all extranodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
Timepoint [9] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [10] 0 0
Number of Participants With OR Following Cross-over to Trametinib - OR is defined as the number of participants with evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 millimeters in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator in participants following cross-over to Trametinib. The evaluation was carried out by the Investigator per RECIST, Version 1.1. Cross-over Population included the subset of participants who were randomized to CT and who elected to cross-over to Trametinib following disease progression on CT. Only participants who received at least one dose of Trametinib were included in this population.
Timepoint [10] 0 0
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
Secondary outcome [11] 0 0
Duration of Response (DoR) for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Investigator Review - DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause. DoR for the investigator-assessed (INVA) response data were summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Timepoint [11] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [12] 0 0
DoR for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Independent Review - DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause. DoR for the independently-assessed (INDA) response data were summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Timepoint [12] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [13] 0 0
DoR for All Confirmed Responders (CR or PR) as Assessed by the Investigator Review - DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR for the INVA response data was summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Timepoint [13] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [14] 0 0
DoR for All Confirmed Responders (CR or PR) as Assessed by the Independent Review - DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR for the INDA response data was summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Timepoint [14] 0 0
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Secondary outcome [15] 0 0
DoR for All Responders (CR or PR) Following Cross-over to Trametinib as Assessed by the Investigator - DoR is defined as the time from the first documented evidence of CR (disappearance of all extra nodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR data were summarized per RECIST, Version 1.1Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Timepoint [15] 0 0
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
Secondary outcome [16] 0 0
PFS Following Cross-over to Trametinib as Assessed by the Investigator - PFS is defined as the time from the first dose of cross-over therapy to the first documented occurrence of PD or death. PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Timepoint [16] 0 0
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)

Eligibility
Key inclusion criteria
- =18 years of age

- Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which
is also determined to be BRAF V600E/K mutation-positive by the central laboratory

- Received no prior treatment or up to one prior regimen of chemotherapy for advanced or
metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior
ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy,
biological or vaccine regimen is permitted. Prior use of sorafenib is allowed

- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST
1.1)

- Women of childbearing potential and men with reproductive potential must agree to use
effective contraception during the study. Additionally women of childbearing potential
must have a negative serum pregnancy test within 14 days prior to randomization

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

- Adequate screening organ function
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any prior use of BRAF inhibitors or MEK inhibitors.

- Subjects who have received dacarbazine or paclitaxel prior to randomization will not
be eligible to receive the same chemotherapy as study medication (i.e. a subject who
received prior dacarbazine cannot receive dacarbazine on this trial and would thus
receive paclitaxel if randomized to the control arm)

- History of another malignancy. Exception: Subjects who have been disease-free for 3
years, or subjects with a history of completely resected non-melanoma skin cancer or
successfully treated in situ carcinoma are eligible. Subjects with second malignancies
that are indolent or definitively treated may be enrolled. Consult GSK Medical Monitor
if unsure whether second malignancies meet requirements specified above

- Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C
Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection
which will be allowed)

- Brain metastases with the following exceptions that are ALL confirmed by the GSK
Medical Monitor:

All known lesions must be previously treated with surgery or stereotactic radiosurgery, and
Brain lesion(s), if still present, must be confirmed stable (i.e. no increase in lesion
size) for =90 days prior to randomization (must be documented with two consecutive MRI or
CT scans using contrast), and asymptomatic with no corticosteroids requirement for = 30
days prior to randomization, and no enzyme-inducing anticonvulsants for = 30 days prior to
randomization

- History or evidence of cardiovascular risk including any of the following:

- QTcB = 480 msec.

- History or evidence of current clinically significant uncontrolled arrhythmias.
Exception: Subjects with controlled atrial fibrillation for >30 days prior to
randomization are eligible

- History of acute coronary syndromes (including myocardial infarction and unstable
angina), coronary angioplasty, or stenting within 6 months prior to
randomization.

- History or evidence of current = Class II congestive heart failure as defined by
New York Heart Association

- History of interstitial lung disease or pneumonitis

- History or current evidence / risk of retinal vein occlusion (RVO) or central serous
retinopathy (CSR):

- History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled
glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes
mellitus, or history of hyperviscosity or hypercoagulability syndromes).

- Visible retinal pathology as assessed by ophthalmic exam that is considered a
risk factor for RVO or CSR such as:

- Evidence of new optic disc cupping.

- Intraocular pressure > 21 mm Hg as measured by tonography

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Garran
Recruitment hospital [2] 0 0
GSK Investigational Site - Port Macquarie
Recruitment hospital [3] 0 0
GSK Investigational Site - Waratah
Recruitment hospital [4] 0 0
GSK Investigational Site - South Brisbane
Recruitment hospital [5] 0 0
GSK Investigational Site - Townsville
Recruitment hospital [6] 0 0
GSK Investigational Site - Woolloongabba
Recruitment hospital [7] 0 0
GSK Investigational Site - Kurralta Park
Recruitment hospital [8] 0 0
GSK Investigational Site - Woodville
Recruitment hospital [9] 0 0
GSK Investigational Site - Heidelberg
Recruitment hospital [10] 0 0
GSK Investigational Site - Melbourne
Recruitment postcode(s) [1] 0 0
2606 - Garran
Recruitment postcode(s) [2] 0 0
2444 - Port Macquarie
Recruitment postcode(s) [3] 0 0
2300 - Waratah
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
4810 - Townsville
Recruitment postcode(s) [6] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [7] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [8] 0 0
5011 - Woodville
Recruitment postcode(s) [9] 0 0
3084 - Heidelberg
Recruitment postcode(s) [10] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
New Jersey
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
South Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
Argentina
State/province [11] 0 0
Ciudad Autonoma de Buenos Aires
Country [12] 0 0
Austria
State/province [12] 0 0
Graz
Country [13] 0 0
Austria
State/province [13] 0 0
Wien
Country [14] 0 0
Belgium
State/province [14] 0 0
Brussels
Country [15] 0 0
Belgium
State/province [15] 0 0
Charleroi
Country [16] 0 0
Belgium
State/province [16] 0 0
Gent
Country [17] 0 0
Belgium
State/province [17] 0 0
Jette
Country [18] 0 0
Belgium
State/province [18] 0 0
Kortrijk
Country [19] 0 0
Belgium
State/province [19] 0 0
Leuven
Country [20] 0 0
Belgium
State/province [20] 0 0
Wilrijk
Country [21] 0 0
Belgium
State/province [21] 0 0
Yvoir
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
British Columbia
Country [24] 0 0
Canada
State/province [24] 0 0
Nova Scotia
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
Czechia
State/province [27] 0 0
Hradec Kralove
Country [28] 0 0
Czechia
State/province [28] 0 0
Ostrava
Country [29] 0 0
Czechia
State/province [29] 0 0
Praha 2
Country [30] 0 0
Czechia
State/province [30] 0 0
Zlin
Country [31] 0 0
France
State/province [31] 0 0
Boulogne-Billancourt
Country [32] 0 0
France
State/province [32] 0 0
Grenoble
Country [33] 0 0
France
State/province [33] 0 0
Montpellier
Country [34] 0 0
France
State/province [34] 0 0
Nantes
Country [35] 0 0
France
State/province [35] 0 0
Paris Cedex 10
Country [36] 0 0
France
State/province [36] 0 0
Pierre-Benite cedex
Country [37] 0 0
France
State/province [37] 0 0
Rennes
Country [38] 0 0
France
State/province [38] 0 0
Tours
Country [39] 0 0
France
State/province [39] 0 0
Villejuif
Country [40] 0 0
Germany
State/province [40] 0 0
Baden-Wuerttemberg
Country [41] 0 0
Germany
State/province [41] 0 0
Bayern
Country [42] 0 0
Germany
State/province [42] 0 0
Niedersachsen
Country [43] 0 0
Germany
State/province [43] 0 0
Nordrhein-Westfalen
Country [44] 0 0
Germany
State/province [44] 0 0
Sachsen
Country [45] 0 0
Germany
State/province [45] 0 0
Schleswig-Holstein
Country [46] 0 0
Germany
State/province [46] 0 0
Berlin
Country [47] 0 0
Greece
State/province [47] 0 0
Athens
Country [48] 0 0
Greece
State/province [48] 0 0
Thessaloniki
Country [49] 0 0
Italy
State/province [49] 0 0
Lombardia
Country [50] 0 0
Italy
State/province [50] 0 0
Toscana
Country [51] 0 0
New Zealand
State/province [51] 0 0
Christchurch
Country [52] 0 0
New Zealand
State/province [52] 0 0
Dunedin
Country [53] 0 0
New Zealand
State/province [53] 0 0
Newtown, Wellington
Country [54] 0 0
Norway
State/province [54] 0 0
Oslo
Country [55] 0 0
Poland
State/province [55] 0 0
Poznan
Country [56] 0 0
Poland
State/province [56] 0 0
Warszawa
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Chelyabinsk
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Magnitogorsk
Country [59] 0 0
Russian Federation
State/province [59] 0 0
Moscow
Country [60] 0 0
Russian Federation
State/province [60] 0 0
St. Petersburg
Country [61] 0 0
Sweden
State/province [61] 0 0
Goteborg
Country [62] 0 0
Sweden
State/province [62] 0 0
Linkoping
Country [63] 0 0
Sweden
State/province [63] 0 0
Lund
Country [64] 0 0
Sweden
State/province [64] 0 0
Stockholm
Country [65] 0 0
Sweden
State/province [65] 0 0
Uppsala
Country [66] 0 0
Switzerland
State/province [66] 0 0
Zurich
Country [67] 0 0
Ukraine
State/province [67] 0 0
Dnepropetrovsk
Country [68] 0 0
Ukraine
State/province [68] 0 0
Kharkiv
Country [69] 0 0
Ukraine
State/province [69] 0 0
Kyiv
Country [70] 0 0
Ukraine
State/province [70] 0 0
Lviv
Country [71] 0 0
Ukraine
State/province [71] 0 0
Sumy
Country [72] 0 0
Ukraine
State/province [72] 0 0
Sympheropol
Country [73] 0 0
Ukraine
State/province [73] 0 0
Ternopil
Country [74] 0 0
Ukraine
State/province [74] 0 0
Uzhgorod
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Cambridgeshire
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Middlesex
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Surrey
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Aberdeen
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Birmingham
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Chelmsford
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Leeds
Country [82] 0 0
United Kingdom
State/province [82] 0 0
London
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Manchester
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Oxford
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a two-arm, open-label, randomized Phase III study comparing single agent GSK1120212
to chemotherapy (either dacarbazine or paclitaxel) in subjects with Stage IIIc or Stage IV
malignant cutaneous melanoma. All subjects must have a BRAF mutation-positive tumour sample.
Subjects who have received up to one prior regimen of chemotherapy in the advanced or
metastatic melanoma setting will be enrolled into the study. Subjects with any prior BRAF or
MEK inhibitor use will be excluded. Approximately 297 subjects will be enrolled with 2:1
randomization (198 subjects into the GSK1120212 arm and 99 subjects into the chemotherapy
arm). The primary endpoint for the statistical analysis will be a comparison of progression
free survival for subjects receiving GSK1120212 compared to chemotherapy. Subjects who have
progression on chemotherapy will be offered the option to receive GSK1120212.
Trial website
https://clinicaltrials.gov/show/NCT01245062
Trial related presentations / publications
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications